Search | Clinical Trials Finder

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 81
States / cities: Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more

Conditions: Non-proliferative Diabetic Retinopathy
Interventions: KSI-301, Sham injection; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 46
States / cities: Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 42 more

Conditions: Bone Marrow Stem Cell Transplant
Interventions: Valganciclovir; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Age-related Macular Degeneration, Diabetic Vascular Diseases, Proliferative Retinopathy, Retina Vein Occlusion
Interventions: Chlorhexidine, Povidine-Iodine; Drug
Lead sponsor: MidAtlantic Retina; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Allergic Conjunctivitis
Interventions: Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo; Drug
Lead sponsor: Fovea Pharmaceuticals SA; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Glaucoma
Interventions: Acetaminophen; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glaucoma, Open-Angle
Interventions: Travoprost Intraocular Implant, iStent infinite, Sham procedure; Drug · Device · Other
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Metamorphopsia, Aniseikonia
Interventions: Aegenta VR; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Vision, Low, Blindness
Interventions: Interaction with Mock COVID-19 Rapid Antigen Test and Reference Surfaces, Biomechanical Measurements, Psychophysical Tasks; Diagnostic Test · Behavioral
Lead sponsor: University of Delaware; Other
Eligibility: 12 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Ocular Inflammation
Interventions: Loteprednol Etabonate, Vehicle of Ophthalmic Loteprednol Etabonate; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Glaucoma
Interventions: Medication reminder, Medication monitoring only; Behavioral
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 8
States / cities: Augusta, Georgia • Grovetown, Georgia • Louisville, Georgia + 4 more

Conditions: Presbyopia Correction, Presbyopia, Dysphotopsia, Visual Acuity
Interventions: TECNIS PureSee IOL (Model DEN00V/DET150), TECNIS Odyssey IOL (Model DRN00V/DRT150); Device
Lead sponsor: Dr. Daniel H. Chang, MD; Other
Eligibility: 22 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Bakersfield, California

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma
Interventions: PF-03187207 and Latanoprost Vehicle, Latanoprost 0.005% and PF-03187207 Vehicle; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 19
States / cities: Artesia, California • Newport Beach, California • Petaluma, California + 15 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: DE-112, DE-112 Vehicle Solution, Timolol Maleate Solution; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Austin, Texas • San Antonio, Texas

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Alcon Investigational Agent; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Allergic Conjunctivitis
Interventions: Vehicle, Brimonidine Tartrate 0.01%, Brimonidine Tartrate 0.025%, Oxymetazoline HCl 0.025%; Drug
Lead sponsor: Eye Therapies, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Retinal Vascular Disease
Interventions: Swept-Source Optical Coherence Tomography; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Low Vision Aids
Interventions: At Home Use; Device
Lead sponsor: Brooks Rehabilitation; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Intravitreal Injection, Ocular Rinse, Age-Related Macular Degeneration, Diabetic Macular Edema, Cystoid Macular Edema
Interventions: OSDI questionnaire, SPEEDII questionnaire; Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 100 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Type 2 Diabetes
Interventions: IcoSema, Insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 43
States / cities: Birmingham, Alabama • Concord, California • La Jolla, California + 37 more

Conditions: Visual Snow Syndrome, Migraine, Healthy
Interventions: Visual Adaptation, Assessments and Questionnaires, Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Imaging (MRS); Behavioral · Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Sleep Disorder, Blindness
Interventions: Melatonin; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 5 Years to 20 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Primary Open Angle Glaucoma or Ocular Hypertension
Interventions: Netarsudil ophthalmic solution 0.02%, Artificial tears; Drug
Lead sponsor: East Coast Institute for Research; Network
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Interventions: Glycerol Tributyrate; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)

The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.

Comfort and Antimicrobial Efficacy of Chlorhexidine vs Betadine for Intravitreal Injections

Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

Does Oral Acetaminophen Lower Intraocular Pressure?

Travoprost Intraocular Implant + iStent Infinite

Virtual Reality Aniseikonia and Metamorphopsia Testing

Validation of Texture Changing Coatings for Use in At-Home Rapid Tests

Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery

Real-time Glaucoma Medication Adherence

Clinical Evaluation of Visual Performance, Spectacle Independence, and Patient Satisfaction With TECNIS PureSee Mini-Monovision and TECNIS PureSee-TECNIS Odyssey Mix-Match

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70

A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)

Swept-Source Optical Coherence Tomography for Noninvasive Retinal Vascular Imaging

Assessing the Impact of eSight Go At-Home Usage in Individuals With Visual Impairment

The Effect of Ocular Rinse Volume on Surface Irritation After Intravitreal Injections

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

Investigating Brain Function in People With and Without Visual Snow Syndrome Using Adaptation to Visual Stimuli

Melatonin Studies of Totally Blind Children

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)